2939-05-1 Usage
Uses
Used in Pharmaceutical Industry:
1H-Imidazole,2-(bromoMethyl)-,hydrobromide(1:1) is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique chemical structure allows it to be a key component in the development of new medications, contributing to the advancement of pharmaceutical research and drug discovery.
Used in Organic Chemistry Research:
In the field of organic chemistry, 1H-Imidazole,2-(bromoMethyl)-,hydrobromide(1:1) serves as a valuable reagent for conducting various chemical reactions. Its versatility in reacting with different compounds makes it an essential tool for researchers in exploring new chemical pathways and synthesizing novel organic compounds.
Used in Chemical Synthesis:
1H-Imidazole,2-(bromoMethyl)-,hydrobromide(1:1) is employed in the synthesis of organic compounds, where its bromomethyl group can be used to introduce bromine atoms into target molecules. This property is particularly useful in the development of new organic materials, agrochemicals, and specialty chemicals, enhancing the range of applications for 1H-IMidazole,2-(broMoMethyl)-,hydrobroMide(1:1).
Check Digit Verification of cas no
The CAS Registry Mumber 2939-05-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,9,3 and 9 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 2939-05:
(6*2)+(5*9)+(4*3)+(3*9)+(2*0)+(1*5)=101
101 % 10 = 1
So 2939-05-1 is a valid CAS Registry Number.
2939-05-1Relevant academic research and scientific papers
Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A2AReceptor
Amelia, Tasia,Van Veldhoven, Jacobus P. D.,Falsini, Matteo,Liu, Rongfang,Heitman, Laura H.,Van Westen, Gerard J. P.,Segala, Elena,Verdon, Grégory,Cheng, Robert K. Y.,Cooke, Robert M.,Van Der Es, Daan,Ijzerman, Adriaan P.
, p. 3827 - 3842 (2021/05/04)
In this study, we determined the crystal structure of an engineered human adenosine A2A receptor bound to a partial agonist and compared it to structures cocrystallized with either a full agonist or an antagonist/inverse agonist. The interaction between the partial agonist, belonging to a class of dicyanopyridines, and amino acids in the ligand binding pocket inspired us to develop a small library of derivatives and assess their affinity in radioligand binding studies and potency and intrinsic activity in a functional, label-free, intact cell assay. It appeared that some of the derivatives retained the partial agonist profile, whereas other ligands turned into inverse agonists. We rationalized this remarkable behavior with additional computational docking studies.
